{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,20]],"date-time":"2025-08-20T12:52:44Z","timestamp":1755694364001,"version":"3.41.0"},"reference-count":20,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,3]]},"abstract":"<jats:p>Heart failure (HF) affects 6.2 million Americans and is increasing annually in its frequency. Treatment of HF has been at the forefront of medical advancements due to the financial burden on our health care system. As such, changes to the guidelines regarding standard of care have been evolving over the last decade with the recent additions of sacubitril-valsartan and sodium glucose co-transporter-2 inhibitors to standard of care in the treatment of HF. Despite the aforementioned expansions in treatment options, HF continues to have a significant impact on the American health care system. Most recently, a novel drug vericiguat that targets an unprecedented pathway for the treatment of HF was Food and Drug Administration approved for the management of patients with HF with a reduced ejection fraction with a recent hospitalization or need for outpatient intravenous diuretics. In clinical trials, vericiguat was associated with a reduction in death from cardiovascular causes and first hospitalization in comparison to placebo. The aim of this review is to provide a comprehensive literature analysis of the various trials surrounding the approval of vericiguat and to both inform and synthesize the data surrounding the clinical use of vericiguat. The introduction of Vericiguat should be considered as a treatment option in patients to decrease the mortality\/morbidity of HF with reduced ejection fraction and to increase the quality of life.<\/jats:p>","DOI":"10.1097\/crd.0000000000000431","type":"journal-article","created":{"date-parts":[[2022,1,24]],"date-time":"2022-01-24T02:07:34Z","timestamp":1642990054000},"page":"87-92","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":8,"title":["Vericiguat: A Novel Soluble Guanylate Cyclase Stimulator for Use in Patients With Heart Failure"],"prefix":"10.1097","volume":"31","author":[{"given":"Rahul","family":"Gupta","sequence":"first","affiliation":[{"name":"Lehigh Valley Heart Institute, Lehigh Valley Health Network, Allentown, PA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Muling","family":"Lin","sequence":"additional","affiliation":[{"name":"University of South Florida, Morsani College of Medicine, Tampa, FL"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Theresa","family":"Maitz","sequence":"additional","affiliation":[{"name":"Department of Medicine, Lehigh Valley Health Network, Allentown, PA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David J.","family":"Egeler","sequence":"additional","affiliation":[{"name":"Department of Medicine, Lehigh Valley Health Network, Allentown, PA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aayaan","family":"Sood","sequence":"additional","affiliation":[{"name":"Mira Loma High School, Sacramento, CA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wilbert S.","family":"Aronow","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasotha","family":"Rajeswaran","sequence":"additional","affiliation":[{"name":"Lehigh Valley Heart Institute, Lehigh Valley Health Network, Allentown, PA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amy M.","family":"Ahnert","sequence":"additional","affiliation":[{"name":"Lehigh Valley Heart Institute, Lehigh Valley Health Network, Allentown, PA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Apurva V.","family":"Vyas","sequence":"additional","affiliation":[{"name":"Lehigh Valley Heart Institute, Lehigh Valley Health Network, Allentown, PA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William H.","family":"Frishman","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine"},{"name":"Division of Cardiology, Westchester Medical Center and New York Medical College, Valhalla, NY."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gregg M.","family":"Lanier","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Westchester Medical Center and New York Medical College, Valhalla, NY."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2022,1,21]]},"reference":[{"key":"R1-20250619","doi-asserted-by":"crossref","first-page":"e56","DOI":"10.1161\/CIR.0000000000000659","article-title":"Heart disease and stroke statistics-2019 update: a report from the American Heart Association.","volume":"139","author":"Benjamin","year":"2019","journal-title":"Circulation"},{"key":"R2-20250619","doi-asserted-by":"crossref","first-page":"e13353","DOI":"10.2196\/13353","article-title":"Impact on readmission reduction among heart failure patients using digital health monitoring: feasibility and adoptability study.","volume":"7","author":"Park","year":"2019","journal-title":"JMIR Med Inform"},{"key":"R3-20250619","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.ahj.2017.01.003","article-title":"Trends in health care expenditure among US adults with heart failure: the Medical Expenditure Panel Survey 2002-2011.","volume":"186","author":"Echouffo-Tcheugui","year":"2017","journal-title":"Am Heart J"},{"key":"R4-20250619","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.jchf.2017.08.013","article-title":"A multicenter, randomized, double-blind, placebo-controlled trial of the efficacy and safety of the oral soluble guanylate cyclase stimulator: the VICTORIA trial.","volume":"6","author":"Armstrong","year":"2018","journal-title":"JACC Heart Fail"},{"key":"R5-20250619","doi-asserted-by":"crossref","first-page":"1847","DOI":"10.1080\/14656566.2021.1937121","article-title":"Vericiguat for the treatment of heart failure: mechanism of action and pharmacological properties compared with other emerging therapeutic options.","volume":"22","author":"Hulot","year":"2021","journal-title":"Expert Opin Pharmacother"},{"key":"R6-20250619","doi-asserted-by":"crossref","first-page":"2263","DOI":"10.1161\/CIRCULATIONAHA.110.981738","article-title":"Soluble guanylate cyclase as an emerging therapeutic target in cardiopulmonary disease.","volume":"123","author":"Stasch","year":"2011","journal-title":"Circulation"},{"key":"R7-20250619","first-page":"w10049","article-title":"Vericiguat in heart failure\u2014who benefits the most?","volume":"24","author":"Mattia","year":"2021","journal-title":"Cardiovascular Medicine"},{"key":"R8-20250619","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1001\/jama.2015.15734","article-title":"Effect of vericiguat, a soluble guanylate cyclase stimulator, on natriuretic peptide levels in patients with worsening chronic heart failure and reduced ejection fraction: the SOCRATES-REDUCED randomized trial.","volume":"314","author":"Gheorghiade","year":"2015","journal-title":"JAMA"},{"key":"R9-20250619","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1093\/eurheartj\/ehw593","article-title":"Vericiguat in patients with worsening chronic heart failure and preserved ejection fraction: results of the SOluble guanylate Cyclase stimulatoR in heArT failurE patientS with PRESERVED EF (SOCRATES-PRESERVED) study.","volume":"38","author":"Pieske","year":"2017","journal-title":"Eur Heart J"},{"key":"R10-20250619","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1056\/NEJMoa1915928","article-title":"Vericiguat in patients with heart failure and reduced ejection fraction.","volume":"382","author":"Armstrong","year":"2020","journal-title":"N Engl J Med"},{"key":"R11-20250619","doi-asserted-by":"crossref","first-page":"1512","DOI":"10.1001\/jama.2020.15922","article-title":"Effect of vericiguat vs placebo on quality of life in patients with heart failure and preserved ejection fraction: the VITALITY-HFpEF randomized clinical trial.","volume":"324","author":"Armstrong","year":"2020","journal-title":"JAMA"},{"key":"R12-20250619","doi-asserted-by":"crossref","first-page":"1952","DOI":"10.1056\/NEJMe2006855","article-title":"Vericiguat\u2014another victory for targeting cyclic GMP in heart failure.","volume":"382","author":"Burnett","year":"2020","journal-title":"N Engl J Med"},{"key":"R13-20250619","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1001\/jamacardio.2020.6455","article-title":"Clinical outcomes and response to vericiguat according to index heart failure event: insights from the VICTORIA trial.","volume":"6","author":"Lam","year":"2021","journal-title":"JAMA Cardiol"},{"key":"R14-20250619","doi-asserted-by":"crossref","DOI":"10.1016\/j.cardfail.2021.05.016","article-title":"Clinical Outcome Predictions for the VerICiguaT Global Study in Subjects With Heart Failure With Reduced Ejection Fraction (VICTORIA) Trial.","author":"Mentz","year":"2021","journal-title":"J Card Fail"},{"key":"R15-20250619","doi-asserted-by":"crossref","first-page":"2631","DOI":"10.1007\/s12325-021-01681-2","article-title":"Budget impact analysis of vericiguat for the treatment of chronic heart failure with reduced ejection fraction following a worsening event.","volume":"38","author":"Alsumali","year":"2021","journal-title":"Adv Ther"},{"key":"R16-20250619","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1007\/s00228-020-03023-7","article-title":"Safety, pharmacodynamic, and pharmacokinetic characterization of vericiguat: results from six phase I studies in healthy subjects.","volume":"77","author":"Boettcher","year":"2021","journal-title":"Eur J Clin Pharmacol"},{"key":"R17-20250619","doi-asserted-by":"crossref","first-page":"650","DOI":"10.2459\/JCM.0000000000000850","article-title":"New drugs for the treatment of chronic heart failure with a reduced ejection fraction: what the future may hold.","volume":"20","author":"Sciatti","year":"2019","journal-title":"J Cardiovasc Med (Hagerstown)"},{"key":"R18-20250619","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1001\/jama.2020.10262","article-title":"Heart failure with reduced ejection fraction: a review.","volume":"324","author":"Murphy","year":"2020","journal-title":"JAMA"},{"key":"R19-20250619","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1056\/NEJMoa1409077","article-title":"Angiotensin-neprilysin inhibition versus enalapril in heart failure.","volume":"371","author":"McMurray","year":"2014","journal-title":"N Engl J Med"},{"key":"R20-20250619","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","article-title":"Dapagliflozin in patients with heart failure and reduced ejection fraction.","volume":"381","author":"McMurray","year":"2019","journal-title":"N Engl J Med"}],"container-title":["Cardiology in Review"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/CRD.0000000000000431","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,19]],"date-time":"2025-06-19T16:01:33Z","timestamp":1750348893000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/CRD.0000000000000431"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,21]]},"references-count":20,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.1097\/crd.0000000000000431","relation":{},"ISSN":["1061-5377"],"issn-type":[{"type":"print","value":"1061-5377"}],"subject":[],"published":{"date-parts":[[2022,1,21]]}}}